Back

Implications of new CV risk reduction indication of PCSK9 inhibitors - Focus on ODYSSEY outcomes

1 September 2019 (10:15 - 10:45)
Organised by:
Congress Presentation Part of: Implications of new CV risk reduction indication of PCSK9 inhibitors - Focus on ODYSSEY outcomes Risk Factors and Prevention ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Gaetano Maria De Ferrari

University of Turin, Turin (Italy)

Access the full session

Session thumbnail
Implications of new CV risk reduction indication of PCSK9 inhibitors - Focus on ODYSSEY outcomes

The Event

Event poster

ESC Congress 2019

1 September 2019 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Coronary risk reduction intervention for siblings and offspring of patients with premature coronary heart disease: the criso project.
thumbnail
ESC TV Today
Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty
thumbnail
Webinar
Risk assessment and lipid management in primary prevention

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources